The stock's fall snapped a three-day winning streak.

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor ...

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight ...

Equities research analysts at Evercore ISI assumed coverage on shares of Bio-Techne (NASDAQ:TECH – Get Free Report) in a ...

Fintel reports that on March 18, 2025, Evercore ISI Group initiated coverage of Bio-Techne (NasdaqGS:TECH) with a Outperform ...

Evercore ISI initiated coverage of Bio-Techne (TECH) with an Outperform rating and $75 price target The firm believes that current volatility ...

In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates ...

Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its ...

Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed ...

Bio-Techne Corp. closed 27.36% short of its 52-week high of $85.57, which the company reached on May 15th.

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Based in Minneapolis, Bio-Techne develops and markets protein-based instruments and reagents for research and clinical use. Its customers include companies in the pharmaceutical and biotech ...